Cargando…
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
OBJECTIVES: To compare the pharmacokinetics (PK), safety and efficacy of innovator infliximab (INX) and CT-P13, a biosimilar to INX, in patients with active ankylosing spondylitis (AS). METHODS: Phase 1 randomised, double-blind, multicentre, multinational, parallel-group study. Patients were randomi...
Autores principales: | Park, Won, Hrycaj, Pawel, Jeka, Slawomir, Kovalenko, Volodymyr, Lysenko, Grygorii, Miranda, Pedro, Mikazane, Helena, Gutierrez-Ureña, Sergio, Lim, MieJin, Lee, Yeon-Ah, Lee, Sang Joon, Kim, HoUng, Yoo, Dae Hyun, Braun, Jürgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786643/ https://www.ncbi.nlm.nih.gov/pubmed/23687259 http://dx.doi.org/10.1136/annrheumdis-2012-203091 |
Ejemplares similares
-
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
por: Park, Won, et al.
Publicado: (2017) -
Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007) -
Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009) -
Coexistence of rheumatoid arthritis and ankylosing spondylitis
por: Barczyńska, Tacjana Anna, et al.
Publicado: (2015) -
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
por: Park, Won, et al.
Publicado: (2016)